论文部分内容阅读
目的通过对江门市区12365例35～69岁妇女乳腺癌筛查,了解地区乳腺癌患病状况及相关因素,为减少乳腺癌发生提出更有效的干预措施。方法乳腺筛查以临床检查为主、选择乳腺钼靶或乳腺彩超诊断,采用(BI-RADS)分级报告,可疑病例作活检。结果乳腺癌检出率为153.7/十万;﹥50岁妇女乳腺癌检出率较﹤50岁妇女高,差异有统计学意义。乳腺良性疾病史与乳腺癌有相关性,差异有统计学意义。乳腺钼靶与乳腺彩超报告为5级的,乳腺癌及癌前病变检出率92%～93%;报告为4级的,乳腺癌及癌前病变检出率为17%～19%,明显高于报告为0～3级。结论乳腺癌筛查可发现早期癌和癌前病变,40～49岁是妇女良性疾病、癌前病变的发病高峰期,而﹥50岁妇女为乳腺癌高发人群,故筛查人群应以40～60岁妇女为主。在基层开展乳腺筛查采用临床检查为主,乳腺超声和钼靶X检查相结合的方式更具优势。BI-RADS分级诊断报告有利于临床医生对诊断结果作风险评估,具有相当的临床应用价值。
Objective To screen 12,365 women aged 35 ~ 69 years in Jiangmen City for breast cancer screening, understand the prevalence of breast cancer in the region and related factors, and to provide more effective interventions to reduce the incidence of breast cancer. Methods Breast screening was mainly based on clinical examination. Breast mammography or breast ultrasonography was used to diagnose breast cancer. BI-RADS was used to report grading and suspicious cases were biopsied. Results The detection rate of breast cancer was 153.7 per 100,000. The detection rate of breast cancer in women> 50 years old was higher than that in women <50 years old. The difference was statistically significant. The history of benign breast disease and breast cancer are related, the difference was statistically significant. Breast mammography and breast ultrasound report was grade 5, the detection rate of breast cancer and precancerous lesions was 92% to 93%; reported as grade 4, the detection rate of breast cancer and precancerous lesions was 17% to 19%, significantly Higher than the report is 0 to 3 levels. Conclusion Breast cancer screening can detect early cancer and precancerous lesions, 40 to 49 years old is a woman’s benign disease, precancerous lesions at the peak, and> 50 years old women are high incidence of breast cancer, so the screening population should be 40 ~ 60-year-old women dominated. Breast screening at the grassroots level with clinical examination, breast ultrasound and molybdenum X-ray examination combined with more advantages. BI-RADS grading diagnostic report is conducive to clinicians for risk assessment of diagnostic results, with considerable clinical value.